Welcome to the Newsroom
28 January 2016
US Patent grants for IMP731 Antibody
SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (“Prima”, the “Company”) announces the granting of patent number US 9,244,059 entitled “Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease” by the United States Patent and Trademark Office.
The patent relates to Prima’s IMP731 antibody (originally developed by Immutep).The granted claims provide protection for specific sequences of the antibody and its use in depleting LAG-3+ T cells by complement dependent cytotoxicity (CDC) and antibody-dependent cell cytotoxicity (ADCC).
Article as pdf